DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: BROVANA

Summary for Tradename: BROVANA

Patents:13
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 BROVANA

Pharmacology for Tradename: BROVANA

Clinical Trials for: BROVANA

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: COPD

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)
Status: Withdrawn Condition: Chronic Obstructive Pulmonary Disease; COPD; Chronic Bronchitis; Emphysema

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: COPD

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Completed Condition: Chronic Obstructive Pulmonary Disease (COPD)

Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography
Status: Recruiting Condition: Chronic Obstructive Pulmonary Disease; COPD; Emphysema; Chronic Bronchitis

A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
Status: Terminated Condition: Acute Asthma

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)
Status: Terminated Condition: Exercise-induced Bronchospasm

Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
Status: Completed Condition: Stable Asthma

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
Status: Completed Condition: Asthma

Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
Status: Completed Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,040,344<disabled>Y<disabled>
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,472,563<disabled>Y<disabled>
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,589,508<disabled><disabled>
Sunovion
BROVANA
arformoterol tartrate
SOLUTION;INHALATION021912Oct 6, 2006RXYes6,667,344<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: BROVANA

Drugname Dosage Strength RLD Submissiondate
arformoterol tartrateInhalation SolutionEq. 0.015 mg base/2 mLBrovana10/1/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc